showme
Prominent proteins in cancer
This is the list of significantly mutated genes (SMGs) and other proteins significantly involved in edgetic perturbations in BLCA.
Perturbation typeGeneCitationCancer typeGene-disease relation
Top gainsLONRF3 (Isoform switch)24486590Urothelial carcinomaArray DNA copy-number data from patients with metastatic urothelial carcinoma
Top gainsRNF146 (Isoform switch)22228636Urothelial carcinomaExpression profiling of high-risk urothelial carcinoma of the urinary bladder
Top gainsSH3BP2 (Isoform switch)9299232Bladder cancerIs located within a common region of deletion at 4p16.3 Involved in bladder cancer
Top lossesGNAQ (Isoform switch)25921176Bladder cancerDown-regulated in metastatic advanced Egyptian bladder cancer
Top gainsBCAN22228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top gainsCATSPER127716384BLCASignificantly altered expression in bladder cancer.
Top gainsFOXD422932667BLCAA region of high-level amplification at 9p24.3 (FOXD4-DMRT2) was present in one tumor.
Top gainsFOXH121063397BLCAOne of frequently upregulated genes on chromosome 8q24.3 in bladder cancer cell lines.
Top gainsGUCY1A229854840BLCAUp-regulated in bladder cancer.
Top gainsHIST1H2AB22228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top gainsHIST1H2AE22228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top gainsHIST1H2BJ22228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top gainsHIST2H2AC30089500BLCADifferentially expressed in tumor samples compared to normal samples.
Top gainsHMGA224571540BLCAExpression of HMGA2; loss of E-cadherin and expression of vimentin are all significantly correlated with bladder cancer grade and stage.
Top gainsKCNJ1030089500BLCADifferentially expressed in tumor samples compared to normal samples
Top gainsLRRC4622228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top gainsMAST122228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top gainsOTX128049011BLCAPotential urinary biomarker for primary nonmuscle invasive bladder cancer.
Top gainsSLX4IP22228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top gainsTMEM52B22228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top cancer-specific gainsDLG127582092BLCA:metastaticMutation in DLG1 is associated with metastatic urothelial carcinoma.
Top cancer-specific gainsDLG322228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top cancer-specific gainsDLG429739919BLCADLG4 is hypermethylated/low-expressed in bladder cancer samples.
Top cancer-specific gainsERBIN25629698UTUC(upper urinary tract urothelial cancer)Involved in urothelial carcinogenesis.
Top cancer-specific gainsGUCY1A229854840BLCAUp-regulated in bladder cancer samples.
Top cancer-specific gainsGUCY1B122228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top cancer-specific gainsHSP90AA127034531BLCAThe smoking-related protein HSP90AA1 and DNA methylation of ECT2 mediate metastasis of bladder cancer.
Top cancer-specific gainsHSPA422228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top cancer-specific gainsLIN7A22228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top cancer-specific gainsSNTA124969694BLCADifferentially expressed in bladder cancer cell lines.
Top cancer-specific gainsSTUB127451077BLCADown-regulated in high grade NMI (non-muscle invasive) bladder cancer.
Top lossesACTA122228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top lossesADCYAP122228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top lossesADRA1D29655996BLCAADRA1D is significantly correlated with lymph node status in bladder cancer patients.
Top lossesAPP30021247BLCAAmyloid precursor protein is upregulated in bladder cancer; and might be closely associated with bladder cancer cell growth and survival.
Top lossesASB1628156048BLCAASB16 belongs to proteins identified with high confidence level in Tn‐negative; blood group A negative; STn‐positive bladder cancer tumor samples recovered from formalin‐fixed paraffin embedded tissues.
Top lossesAURKC29058301BLCA:transitionalDifferentially expressed in transitional bladder cancer samples compared to normal samples
Top lossesAVPR222228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top lossesBEX122228636:21421225BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy. : Involved in urothelial maturation.
Top lossesBMX21408190BLCAETK/BMX is up-regulated in bladder cancer and predicts poor prognosis in patients with cystectomy.
Top lossesCLEC4G22228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top lossesCMTM522228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top lossesEFHC222228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top lossesENPP622228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top lossesFAM124A22228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top lossesFOXD328665070BLCADown-regulated in non-muscle invasive high-grade urothelial carcinoma of the bladder.
Top lossesGPM6A29200870BLCAPotential target for miRNA biomarkers in bladder cancer.
Top lossesGRIN2A24469795BLCAAmplification of GRIN2A in a subset of TCC-UB representing a potential therapeutic target.
Top lossesISL126332997BLCAISL1 showed significantly higher mean methylation in recurrent and progressive tumors compared to non-recurrent tumors.
Top lossesKCNA320025600BLCADifferentially expressed in tumor samples compared to normal samples.
Top lossesKCNA520025600BLCADifferentially expressed in tumor samples compared to normal samples.
Top lossesMEFV22228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top lossesMYH7B22228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top lossesP2RY1230778022BLCAP2RY1 is a target gene of miR-34b-3p; which have a negative regulatory effect on multidrug resistance of bladder cancer
Top lossesPRPH22228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top lossesRUNX1T129963227NMIBC(non-muscle invasive bladder cancer):MIBC ( muscle invasive bladder cancer)Differentially regulated by miR-5701 in non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) cells
Top lossesRXRG22228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top lossesSCN2B21116856BLCADifferentially expressed in bladder cancer cell lines
Top lossesSOX530983072BLCAcircDOCK1 affected the progression of BC via modulation of circDOCK1/hsa-miR-132-3p/Sox5 pathway both in vitro and in vivo.
Top lossesSTX1B22228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top lossesZBTB2022228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top cancer-specific lossesKCNA320025600BLCADifferentially expressed in tumor samples compared to normal samples.
Top cancer-specific lossesFAM124A22228636BLCADifferentially expressed in a high-risk population of patients who underwent radical cystectomy.
Top cancer-specific lossesPIPOX26802582BLCADifferential expression in tumor samples compared to normal samples
SMGs within edgetic gains or lossesATM28138703BLCAATM participates in the regulation of viability and cell cycle via ellipticine in bladder cancer.
SMGs within edgetic gains or lossesCDKN2A30258198MIBC(muscle invasive bladder cancer)CDKN2A RNA expression-based risk stratification of MIBC allows the identification of a CDKN2A high poor prognosis group with low expression of drug target genes.
SMGs within edgetic gains or lossesCTNNB130015971BLCAHuman bladder cancer SW780 cells were identified as having high expression of beta‑catenin (CTNNB1).
SMGs within edgetic gains or lossesCUL127312089BLCACUL1 was dramatically overexpressed in high-grade urothelial carcinoma (UC) tissues compared with low-grade UC tissues.
SMGs within edgetic gains or lossesEP30021935574BLCAp300 (EP300) expression was reduced in doxorubicin-resistant bladder cancer cells and in response to doxorubicin exposure.
SMGs within edgetic gains or lossesERBB329434875BLCAThe high soluble HER3 (ERBB3) levels are associated with improved survival rates in patients with bladder cancer; and that soluble HER3 inhibits bladder cancer cell growth and migration.
SMGs within edgetic gains or lossesFBXW728772241BLCAThe novel overexpressed p65-initiated PTEN/FBW7(FBXW7)/RhoGDIalpha migration regulatory axis provides new insights into the mechanisms of the underlying nature of p65 in regulation of BC cell motility.
SMGs within edgetic gains or lossesKRAS24058630BLCASimultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia.
SMGs within edgetic gains or lossesMDM427798881MIBC(muscle invasive bladder cancer)The low MDM4 expression were associated with recurrence-free and cancer-specific survival in patients with MIBC.
SMGs within edgetic gains or lossesPIK3CA30593515HG-UTUC(high-grade upper tract urothelial cancers)Alterations in PIK3CAcorrelated with worse overall survival in HG-UTUC and occurred concurrently.
SMGs within edgetic gains or lossesPSIP117363574BLCAPSIP1(LEDGF) expression is increased in human breast and bladder carcinomas correlating with that of Hsp70-2 in invasive bladder cancer.
SMGs within edgetic gains or lossesPTEN30575901:30719818BLCAMiR-103/107 regulates cell proliferation and PI3K/AKT signaling partially through PTEN dependent mechanism. Nuclear PTMA protein serves as a tumor suppressor in bladder cancer through upregulating PTEN and orchestrating TRIM21 for the regulation of Nrf2 signaling.
SMGs within edgetic gains or lossesRB124476821BLCARecurrent mutation in RB1.
SMGs within edgetic gains or lossesRBM1030852032BLCAThe loss of RBM10 expression is observed across all bladder tumor stages and grades; suggesting that it is an early event in tumor progression.
SMGs within edgetic gains or lossesSPTAN123452234BLCAThe significant expression in the group of patients without recurrence.
SMGs within edgetic gains or lossesTP5328760909BLCADeleterious alterations in TP53.
SMGs within edgetic gains or lossesTSC128760909BLCATruncating mutations in TSC1.

To download a file, either filter the gene of interest or select all the entries and then press the "Download as Excel table" button